Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Angiogenesis Stories

2011-10-31 08:50:00

MELBOURNE, Australia, Oct. 31, 2011 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate clinical trials of VGX-100. The first trial (Phase I) will study VGX-100 in patients with a variety of late stage cancers. "The FDA's acceptance of our IND represents an extremely important...

2011-10-24 23:09:24

Targeting specific addresses could help fight cancer, obesity and other diseases A research team led by scientists from The University of Texas MD Anderson Cancer Center have discovered four new "ZIP codes" in their quest to map the vast blood vessel network of the human body. The study, published online the week of Oct. 24 in the Proceedings of the National Academy of Sciences, brings science one step closer to the goal of using the vascular system to personalize cancer therapy, as...

2011-09-30 08:21:00

MELBOURNE, Australia, Sept. 30, 2011 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer. VGX-100 is a human antibody...

2011-09-23 06:15:00

CAMBRIDGE, Mass., Sept. 23, 2011 /PRNewswire/ -- Efficacy and safety data from VELOUR, the pivotal Phase III trial of aflibercept (VEGF Trap, ZALTRAP(TM)) for the treatment of metastatic colorectal cancer (mCRC) will be presented by Edith P. Mitchell, M.D., a leading cancer researcher, at the Angiogenesis Foundation's 9th Annual M. Judah Folkman International Conference: Antiangiogenesis: New Frontiers in Therapeutic Development on October 29-30, 2011 at the Hyatt Regency Cambridge. The...

2011-09-16 13:54:00

CLEVELAND, Sept. 16, 2011 /PRNewswire/ -- Recent advances in regenerative medicine show stem cell therapy may ultimately be used to create new blood vessels (angiogenesis), improve heart function and reduce the risk of amputation in patients with peripheral vascular disease. Yet an obstacle stands in the way of realizing the promise of these breakthroughs: Autologous endothelial progenitor stem cells (i.e., adult "self" stem cells) compose a very small fraction of the cells in the...

2011-09-13 08:00:00

MELBOURNE, Australia, Sept. 13, 2011 /PRNewswire/ -- Data published in the scientific journal Archives of Ophthalmology generated by investigators at the Schepens Eye Research Institute led by Harvard University Professor Reza Dana. VGX-100 significantly reduced inflammation and corneal epitheliopathy in a mouse model of Dry Eye Disease. Data indicates major potential opportunity for VGX-100 as a therapeutic for Dry Eye Disease. Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY)...

2011-09-01 12:06:42

Discovery could highlight a new avenue for drug development to combat neurodegenerative disorder University of British Columbia scientists may have uncovered a new explanation for how Alzheimer's disease destroys the brain — a profusion of blood vessels. While the death of cells, whether they are in the walls of blood vessels or in brain tissue, has been a major focus of Alzheimer's disease research, a team led by Wilfred Jefferies, a professor in UBC's Michael Smith Laboratories,...

2011-09-01 11:30:13

The Findings Open the Door to the Development of Novel Drugs for Early-Stage Tumors Scientists at The Scripps Research Institute have shown that a particular white blood cell plays a direct role in the development and spread of cancerous tumors. Their work sheds new light on the development of the disease and points toward novel strategies for treating early-stage cancers. The study was published in September 2011 print issue of the American Journal of Pathology. Scripps Research...

2011-08-18 12:27:00

CAMBRIDGE, Mass., Aug. 18, 2011 /PRNewswire/ -- Leading angiogenesis and cancer researcher Dr. Robert S. Kerbel of the University of Toronto will deliver the Future of Medicine Keynote Address at the Angiogenesis Foundation's 9th International M. Judah Folkman Conference -- New Frontiers in Therapeutic Development. The conference will take place on October 29-30, 2011 in Cambridge, MA, and attracts key opinion leaders from academia, industry and government to discuss the latest scientific...

2011-08-17 15:05:00

TARRYTOWN, N.Y., Aug. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that clinical data from four separate clinical studies of EYLEA(TM) (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Boston, Massachusetts. The presentations are: "Analysis of 2,457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF Trap-Eye and...